Cencora stock trades near record levels as specialty distribution growth supports earnings

Cencora Inc. (ISIN US03073E1055), formerly AmerisourceBergen, has seen Cencora stock trade near its historical highs in 2024 as the companys earnings and cash flow from pharmaceutical distribution and specialty services continue to expand. According to a recent market overview as of 30 June 2024, Cencora shares are quoted around $230 on the New York Stock Exchange, close to their 52 week high of about $233, signaling that investors are pricing in continued growth and resilient demand for its distribution and services platform.

Revenue up over 7 percent in fiscal 2023

Revenue growth has been a central driver for Cencora stock. In its fiscal 2023 annual report, Cencora reported revenue of approximately $262.2 billion, up around 7.3% from roughly $244.4 billion in fiscal 2022, as demand for pharmaceutical distribution, specialty therapies, and manufacturer services increased across the United States and international markets. Adjusted diluted earnings per share for fiscal 2023 were reported at about $11.54, compared with approximately $10.70 in fiscal 2022, reflecting earnings growth of roughly 7.9% year on year and underscoring the companys ability to translate higher volumes into profit expansion.

Operating performance has also been supported by margin discipline. In fiscal 2023, Cencora reported operating income of approximately $2.5 billion, up from about $2.3 billion in fiscal 2022, pointing to mid single digit growth in operating profit despite a low gross margin distribution model. For investors following Cencora stock, the fact that operating income grew alongside revenue highlights the companys focus on efficiency and scale benefits in its network.

Guidance raises the bar for fiscal 2024

Forward looking metrics provide another anchor for Cencora stock valuation. In its guidance for fiscal 2024, the company indicated that it expects adjusted diluted earnings per share in a range of around $12.25 to $12.55, implying mid single digit to high single digit growth versus the fiscal 2023 adjusted EPS of about $11.54. Such a guidance range represents an increase of roughly 6.1% to 8.8% year over year at the midpoint and upper bound, assuming operational conditions remain stable and the specialty distribution and services business continues to expand.

Free cash flow is another metric closely watched by shareholders. According to recent investor relations materials for fiscal 2023, Cencora generated operating cash flow of around $3.5 billion and free cash flow of roughly $3.0 billion after capital expenditures. These figures compare with estimated operating cash flow of about $3.1 billion and free cash flow of nearly $2.7 billion in fiscal 2022, marking growth of approximately 12.9% and 11.1% respectively and reinforcing the companys ability to fund dividends, share repurchases, and strategic investments without stretching its balance sheet.

Dividend policy has complemented earnings growth. In fiscal 2023, Cencora paid an annualized dividend of approximately $1.94 per share, up from about $1.80 per share in fiscal 2022, representing a year on year increase of around 7.8%. While the dividend yield on Cencora stock remains modest given the elevated share price, steady increases signal managements confidence in recurring cash flows from its distribution and services operations.

Specialty distribution supports growth

Beyond headline numbers, the composition of Cencoras business is an important factor for how Cencora stock is valued. The company operates through segments that include pharmaceutical distribution, specialty distribution, and manufacturer services. Specialty distribution has been a particular growth engine, as oncology, rare disease, and complex therapies continue to expand and often require tailored logistics, inventory management, and patient support solutions.

According to recent segment disclosures for fiscal 2023, specialty related revenue is estimated to account for a significant portion of total sales, with specialty and manufacturer services contributing tens of billions of dollars to the consolidated revenue figure. While precise segment revenue data can vary across presentations, the underlying trend shows that specialty activities have grown faster than the core distribution business in recent years, helping lift the overall revenue growth rate above 7% for fiscal 2023 compared with the prior year.

Margins in the specialty business also tend to be higher than in traditional distribution, as services such as patient support, data analytics, and reimbursement assistance command higher value. In fiscal 2023, Cencora reported that adjusted operating margin remained broadly stable despite competitive dynamics and reimbursement pressures, thanks in part to the mix benefit from specialty and manufacturer services and continuous efficiency initiatives in its network.

Cash flow and balance sheet underpin Cencora stock

For long term holders of Cencora stock, the balance sheet and cash flow profile are central to understanding risk and reward. As indicated in fiscal 2023 filings, Cencora ended the year with total debt of roughly $6.3 billion and cash and equivalents of around $2.4 billion, implying net debt of about $3.9 billion. When compared with operating income of approximately $2.5 billion and free cash flow of roughly $3.0 billion, the leverage profile appears manageable, with net debt to operating income comfortably below 2 times and free cash flow exceeding net debt.

Capital allocation has remained diversified. In fiscal 2023, Cencora devoted around $0.4 billion to capital expenditures, focused on technology, logistics infrastructure, and specialty facilities that support long term growth. Additionally, the company returned capital to shareholders through dividends and share repurchases. Share buybacks in fiscal 2023 totaled approximately $0.7 billion, compared with about $0.6 billion in fiscal 2022, demonstrating a willingness to use excess cash to offset dilution and enhance per share metrics when valuation and cash generation allow.

Interest expense has been kept under control despite a rising rate environment. In fiscal 2023, Cencora recorded interest expense of roughly $0.2 billion, only modestly above fiscal 2022 levels, indicating that the company has not significantly increased its leverage or faced severe refinancing headwinds. This helps support the sustainability of free cash flow, which in turn underpins the dividend and share repurchase programs that many Cencora stock investors monitor closely.

Product services and patient support platform

Cencora provides a broad range of product and service offerings across the pharmaceutical value chain, including specialty distribution, third party logistics, and patient support services. Its platform connects manufacturers, pharmacies, hospitals, and physicians, helping ensure that medicines reach patients efficiently and compliantly. The company offers programs that support the introduction of new therapies, such as hub services that coordinate reimbursement, prior authorization, and patient education.

One representative area is oncology and rare disease support, where Cencora collaborates with manufacturers to design distribution and patient access solutions that account for complex handling requirements, cold chain logistics, and often high value therapies. Revenue in these specialty categories has grown faster than the overall pharmaceutical market, bolstering the companys total revenue expansion of roughly 7.3% in fiscal 2023 versus fiscal 2022. For Cencora stock, this translates into a narrative where growth is linked not only to volume of medicines but also to the sophistication of services and data capabilities.

Cencora stock price context and valuation

In the equity market, Cencora stock has benefited from both fundamental growth and broader sector trends. As of 30 June 2024, with the share price around $230 and fiscal 2023 adjusted EPS of approximately $11.54, the stock trades at a trailing price to earnings ratio of about 19.9 times. If investors take the midpoint of the fiscal 2024 adjusted EPS guidance range at roughly $12.40, the forward price to earnings multiple would be near 18.5 times, assuming the share price is unchanged. These valuation levels sit in the context of large cap healthcare and distribution peers and reflect expectations that Cencora can sustain mid single digit to high single digit earnings growth.

The relationship between share price and cash flow is also important. With estimated free cash flow of about $3.0 billion in fiscal 2023 and a market capitalization near $46 billion as of late June 2024, Cencora trades at a free cash flow yield of roughly 6.5%. That metric is calculated by dividing free cash flow by market capitalization and offers investors another lens on valuation, particularly in sectors where earnings may be influenced by working capital swings or non cash items.

Volatility in Cencora stock has generally remained moderate compared with high growth sectors, reflecting its role in an essential service industry. The share price has moved within a 52 week range of approximately $180 to $233, implying a top to bottom spread of around 29.4%. Within that range, periods of macro uncertainty and interest rate shifts have at times weighed on sentiment, while strong quarterly results and raised guidance have supported rallies, keeping the stock near the upper end of its range in recent months.

Fact box: Cencora key data